Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3679)	1/27/1998 12:12:00 AM
From: JOHN W.	Respond to of 6136

"Deja Vu" POZ (02/98) P. 25; Hess, Scott The U.S. Department of Health and Human Services and the U.S. branch of the International AIDS Society (IAS) have published HIV treatment guides that recommend a protease-based three-drug therapy and advise symptom-free HIV-infected individuals to hold off on treatment. The two guides differ on when HIV patients should begin drug regimens. While the HHS guide suggests initiation of treatment when a patient's viral load exceeds 10,000 to 20,000 copier/mL or when the CD4 count falls below 500, the IAS says that treatment should begin when an individual's viral load is between 5,000 and 10,000 copies/mL, regardless of CD4 count. The HHS and IAS guides also differ in their panel membership: the HHS guide was created by doctors, researchers, and industry representatives, while the IAS board is composed of only physicians. HHS panel member Martin Delaney, of Project Inform, observed: "The guidelines disagree in an area where nobody has the absolute answer, so it comes down to expert opinion."